Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts


  • Featured Story


    Stroke kills an American every four minutes - more than 525,000 individuals each year - and nearly 300,000 more fall victim to its debilitating consequences.

    The onset of symptoms signal a dire emergency. According to the National Stroke Association, they can include:

    • Sudden numbness or weakness of the face, arm or leg, especially on one side of the body;
    • Sudden confusion, trouble speaking or understanding;
    • Sudden trouble seeing or blurred vision in one or both eyes; and/or
    • Sudden trouble walking, dizziness, loss of balance or coordination.

    There are two types of stroke: hemorrhagic and ischemic. The first results from a ruptured blood vessel in the brain, and the other from an inadequate blood supply, usually due to a blood clot blocking an artery that feeds the brain. 

    The second variety, ischemic stroke, is by far the more common. Nearly nine out of 10 are of this type. And that's fortunate, because an ischemic stroke could be relatively easy to prevent - provided you see it coming.

    If you had the technology to find and map arterial blockages safely, simply, and quickly, you could intervene with a relatively simple medical procedure, clear the blockage, and bring down that enormous annual incidence of stroke to a much smaller number.

    Does such a technology exist?

    Currently, doctors can use an ultrasound machine to detect the presence of an occlusion (blockage) or stenosis (narrowing) in a carotid or cerebral artery, but the patient then has to undergo a CT scan or MRI for more definitive information.

    It's a complicated, drawn-out, and extremely expensive process, and you would think a single-step, cheaper technology might be a game changer - and represent a windfall for investors.

    One micro-cap biotech in Vancouver, Canada, CVR Medical, is counting on exactly that with its new carotid stenotic scan (CSS) device.

    The device is about to enter pivotal clinical trials, and after they're completed, will go to the U.S. Food and Drug Administration (FDA) for marketing approval.

    The CSS could save the government up to $34 billion a year, according to the CDC, and more importantly, hundreds of thousands of lives in the United States and around the world.

    That's great news for patients and their families. And it has proven a terrific opportunity for investors, too. Since the company's IPO in November 2016, the stock is already up over 90%.

    But here's the thing. This device may not be the silver bullet it's cracked up to be. And the stock isn't, either.

    I'm going to show you what's really happening here and how to ultimately profit on this situation. It's a great example of how independent research can save you a lot of money in the long run...

Article Index

Forget Allergan – Here's Pfizer's Real High-Profit Ace


Big-cap investors were profoundly underwhelmed when the Obama administration caused Pfizer Inc. to cancel a $150 billion buyout of another massive pharma, Allergan Plc.

Like most deal-making at this level, there was a lot at stake. Allergan has a portfolio packed with name-brand drugs with long patent lives and a robust generics business. What's more, the deal would have allowed Pfizer to relocate its headquarters to the (extremely) tax-friendly Republic of Ireland and save a ton on payments to Uncle Sam.

Now, normally when a deal like this falls through, the shares take a serious pounding, but the smart money is holding its nerve. In fact, the stock is up just over 10% year to date. That says a lot.

Those investors, along with folks who buy in right now, stand to be richly rewarded in the future.

That's because there's something bigger - much bigger - than the $150 billion Allergan deal coming down the road...

As Another Sector's Sails Lose Wind, Watch This One Barometer

One by one, the bubbles are bursting...

First it was the commodities bubble that blew up in mid-2014, which caused the collapse of energy and commodity stocks -they are now down between 40-80%.

It also caused the end of the corporate credit bubble in high yield bonds and bank loans over the second half of 2014 and into this year.

Then the Chinese stock market, which had gone parabolic early this year, collapsed, sending global markets into a tailspin this summer.

This Biotech Patent Leader Generates an 8.3% Dividend Yield

Most biotech stocks are growth plays, so you'll almost never find one that pays anything more than a bare bones dividend. But this company has a distinct advantage that allows it to reward its shareholders - big-time. Michael Robinson explains.

Meet the Biotech CEO With a $30 Billion Breakthrough

There's a deadly problem with one of the nation's major medical markets - vaccines.
The technology we use today to prevent diseases like the flu, chicken pox, and polio is hopelessly outdated.
It still relies on the delivery of a portion of the actual virus to the patient to develop immunity. Some of these agents are still grown in chicken eggs, just like they were back in the 1930s. And the vaccines themselves or their additives can still make people sick.
But what if you could develop a whole new class of vaccines that were actually safe using a synthetic DNA? Better yet, what if you could vaccinate yourself against HIV, cervical cancer, leukemia, and hepatitis?
The payoff would be tremendous...

The Next Profit Breakthrough: Synthetic Biology

Drug, chemical, and biofuel firms are relying more than ever on artificial fragments of DNA to invent new products. It's called synthetic biology.

For example, teams all over the world are now in their labs looking to create novel biotech compounds or drugs by inserting synthetic DNA into cells, either living or artificial. They're also growing new microorganisms that yield biofuels to be used in lieu of oil.

Trouble is, the process is so complex that it can take days to synthesize these man-made genes, usually in small batches.

Not only is it time consuming, but it requires the use of costly robots and other advanced gear. Simply stated, if someone came along with a breakthrough that greatly speeded up the development of synthetic genes, it could affect several industries at once, not to mention its own value in the market.

Allow me to introduce you to Gen9 Inc. The company is blazing a trail in the development of scalable technologies for synthesizing genes.

Now, Gen9 is a small, new dynamic company. And its potential is huge.

It was formed last summer around a unique new device that greatly speeds up the process of creating synthetic DNA.

Even better, it cuts the cost of that process by leaps and bounds.

To continue reading, please click here...

Letting Biotech Companies "Patent Nature" Could Be a Huge Boon for Investors

The U.S. Supreme Court has just agreed to hear a landmark case that could have extreme money-making ramifications for biotech companies.

Next June, the nine justices are expected to settle - once and for all - whether companies can patent human genes in the United States.

The Patent and Trademark Office has been issuing patents on DNA for nearly 30 years, according to Bloomberg Businessweek.

Roughly 4,000 of the 22,000 human genes now have some form of patent.

But the American Civil Liberties Union has challenged the practice in Association for Molecular Pathology v. Myriad Genetics. Now that case will go to the highest court in the country.

At heart, the legal question sounds simple: Does Myriad Genetics Inc. (NasdaqGS:MYGN) have the right to patent two genes that signal whether a woman is at higher risk of getting cancer of the breasts or ovaries?

Myriad of course did not invent or create the breast cancer predisposition genes, referred to as BRCA genes.

But it did create something called the BRACAnalysis test that looks for mutations on these genes. Those mutations are associated with much greater risks of breast and ovarian cancer.

Usually firms cannot get that kind of market protection for something that is clearly a product of nature. But in this case, Myriad has developed a process of extracting a gene that makes the resulting molecule novel and chemically different from DNA that naturally occurs in our bodies.

And, after all, it took Myriad 17 years and $500 million to develop the test. Without barriers to entry, other firms could simply come in, take advantage of all that costly effort and sell a knockoff for less money.

Even if that weren't illegal, it's obviously unfair.

Let's dig into the case and why it matters to you...

To continue reading, please click here...

Three Biotech Stocks to Buy Now

If you're looking to hit a home run over the next 12 months, your best bet for stocks to buy now is biotechnology companies - especially those focused on cancer research.

Here's why: biotech stocks have been in a stealth bull market in 2012.

In fact, the values of the 230 publicly-traded biotech companies tracked by the BioWorld Stock Report have jumped by an average 38% year-to-date.

The third quarter was especially hot. The Nasdaq Biotechnology Index rose 10% over that time frame and is up a healthy 37% this year.

And, nothing is hotter than companies focused on the battle against cancer.

Take Medivation Inc. (Nasdaq: MDVN), for example. This California-based biotech has jumped from $23 to $46 a share, largely on the approval of Xtandi, its novel prostate cancer drug.

Thousands of other experimental drugs are going through various stages of clinical trials, and the largest category in the pipeline is cancer drugs. With that in mind, it's safe to say that if you're looking for a stock with big upside potential, cancer-driven biotech stocks should be high on your list. Biotech Stocks: Cancer Research is Paying Off

A cancer diagnosis was once a death sentence -- especially if you were diagnosed with the disease in its late stages.

But, both government and industry have spent vast sums in the last decade researching how cancers develop and spread.

And now all that investment is starting to pay off -- recent clinical trials and treatment breakthroughs show real promise.

The newest cancer research focuses on three fronts.

To continue reading, please click here...

“Cyborg” Tissue Blurs the Line Between Man and Machine

Robots are becoming more human all the time.

I predict that in the near future, robots will be so human-like that it will seem natural for us interact with them. We'll also see the advent of people who are what I call "bionics" - those who put computer chips or other devices in their brains or bodies.

As I see it, we are fast approaching the day in which man and machine become fused together.

Just in the last few days, researchers reported major breakthroughs that promise to do just that. In a moment, I'll tell you all about it.

First, remember the new hydrogel we investigated last Wednesday - the material that could greatly improve human health and aging by replacing damaged cartilage?

Turns out there's another part of the part of the story we need to know about.

This type of hydrogel could play a vital role in the cutting-edge field of robotics, too.

See, we're getting very close to the day in which we augment robots with "smart" human tissue. We'll grow tissue in labs and equip it with onboard electronics made possible by nanotech circuits.

That's where the hydrogel would come in handy. We won't just replace damaged cartilage in people. We'll use that or something like it to link sensor-laden tissue inside robots or in people with organ transplants or artificial limbs.

Just two weeks ago, a research team from MIT and the University of Pennsylvania said they had blurred the boundary between biology and machines even further. They genetically engineered skeletal muscles for robots that work by responding to light.

This is just amazing...

To continue reading, please click here...

Read More…

Five Miraculous New Brain Secrets You Need to Know About

It's the most complex organ on earth - the human brain.

And our understanding of the brain is about to reach critical mass.

Our knowledge of the human brain grows by leaps and bounds almost every week. In just the last two weeks, researchers have made several new breakthroughs crucial to learning more about diseases that can cause mental illness or kill us outright.

I predict that in the near future our knowledge of the brain will become so complete we will find cures for such deadly diseases as Alzheimer's and Parkinson's. The same holds for depression and schizophrenia.

And that's one of the key benefits of living in the Era of Radical Change. What was a deep mystery about the brain (and other areas) just a few months ago is now much better understood.

Of course, the pace of change is nothing short of amazing. Consider that as I was preparing this report on five new brain secrets, I came across two more brand-new advances in brain science. Each one holds great promise in our drive to live, longer, healthier, and smarter lives.

Take a look...

Brain Secret No. 1: SuperAgers Have the Right Kind of "Senior Moments"

For decades, researchers have studied the brains of diseased older patients to see what went "wrong." They focus on the origin of diseases, like Alzheimer's, that cause memory loss or dementia.

But a team at Northwestern University took just the opposite approach - they've been studying the brains of highly alert seniors. And the results give hope to millions of aging Baby Boomers.

Turns out there's an elite group of older folks called "SuperAgers" whose brains seem to defy the effects of aging. In fact, their brains match those of people 30 years younger.

To continue reading, please click here...

"Bionic Eyes" Could Make Blindness a Thing of the Past

Just last week I told you the day of bionic humans is at hand.

Some of you were excited by the possibilities. Take Matt:

"As someone who has bounced back from a severe head injury 25 years ago to do things the brain injury rehab team told me would simply not be possible - complete my bachelor's degree as well as a master's, get married, and subsequently raise a son on my own as a single parent, etc. - I am especially excited about the possibilities at the juncture of neurological research, computing technology, and prosthetics. I will be overjoyed when the day comes that I can once again use both my hands to type 100 words/minute with few to no mistakes, like I could when I first learned to type on an electric typewriter, nearly 40 years ago."

On the other hand, several of you thought it sounded like a nightmare. Here's what Claire had to say:

"Transhumanism is a dark future that is presented as wonderful, but which will alienate those who embrace it from their humanity... Not for me, I would rather remain human."

Either way, it seems bionic tech is actually moving faster than I thought...

Restoring Sight to the Blind

You may recall that I cited two examples of future devices to enhance your eyes. One is a pair of contact lenses, and the other is an implant that would go in your retina. Both could access the wireless Web to keep you connected to the world's vast database of knowledge, wherever you are.

Well, it's come out that at least two companies hope to start selling bionic eyes in the U.S. within the next 16 months.

Neither of these designs is made to surf the Web. Instead, these cutting-edge breakthroughs could help millions of blind or visually impaired people to see again.

Take a look...

To continue reading, please click here...

This Tiny Startup Has Scored "Microchip Medicine" Breakthrough

A tiny startup has received FDA approval to sell a novel new drug-tracking sensor that could literally save your life one day.

It's a "pill" as big as a grain of sand and it could also mean huge profits for Big Pharma companies in the not-too-distant future.

You see, each year millions of American s throw away tons of unused drugs. What happens is they start feeling better and just stop taking their meds. Eventually those pills get tossed in the trash can.

No one seems to know the full dollar value of all those unused drugs but many experts say this waste costs Big Pharma millions in profits in lost refills.

Not only that, but doctors around the world worry about the rise of drug-resistant bacteria which also stems from patients not taking their full regimen of antibiotics.

It's why doctors always tell their patients to take all their antibiotics even after they feel better. Otherwise, the few germs that manage to survive become more powerful and thwart the effects of stronger drugs taken at larger doses.

Enter a tiny new startup called Proteus Digital Health Inc. The company has developed a new electronic sensor that could transform the way millions of Americans manage their drug intake.

The move puts Proteus front and center in the hot new field of "microchip medicine."

Experts call it that because patients either swallow a microchip that releases doses into the bloodstream or ingest a small medical monitor like the one Proteus makes.

Proteus has the backing of a dozen firms. They include:

  1. Novartis AG (NYSE: NVS), one of the world's biggest drug makers.
  2. Medtronic Inc. (NYSE: MDT), a big-cap medical device firm.
  3. Kaiser Permanente Ventures, the venture arm of the large HMO.
  4. On Semiconductor (NASDAQ: ONNN), a mid-cap maker of chips and other devices.
No doubt, Proteus has some great technology behind it. Here's how it works.

To continue reading, please click here...

Man-Made Proteins Put a New Twist on Evolution – And They Fight the Flu

Man-made proteins. You may have never heard of them, but you will.

They are set to become huge change agents in the high-tech world of the very near future.

Some of you may have already heard the recent news that doctors believe they can use these compounds to help fight the flu.

The major media was all over this angle. And no doubt, it's an important advance.

In the U.S. alone, 200,000 people get so sick from the flu they have to go to the hospital each year. U.S. health officials say as many as 50,000 people die.

The version of synthetic protein that can help boost your immune system to fight the flu is called EP67.

Earlier this month, a team from San Diego State University and the University of Nebraska Medical Center tested the substance on mice - with great results.

In a paper that ran in the journal PLoS One, they said mice given a lethal dose of the flu survived after getting an injection of the protein. What's more, it could be used to guard against other diseases, as well.

"Since EP67 works by stimulating local innate immunity, it should prove effective against viral, bacterial and fungal diseases," said Joy Phillips, the study's lead author. She noted said they still need to test the protein on larger mammals and humans.

There is a catch - you have to get a dose of EP67 within 24 hours of exposure to the bug for it to be effective.

Still, clearly, synthetic proteins could have a huge impact on public health.

Yet I believe the media missed the real story.

With a hot new field of science known as "directed evolution," scientists will do far more than treat disease.

They may just redesign our digital universe.

How Directed Evolution Works

The idea is pretty simple. Genetic engineers apply evolutionary design methods to biological systems.

In this way, they seek to "evolve" proteins and organisms that have unique aspects not found in nature. They can have useful applications in medicine, alternative energy, and the like.

Making sense of this new advance requires us to take a look at proteins from a unique point of view.

To continue reading, please click here...

What is the "ASCO Effect"?

Anyone interested in biotech stock profits should know the answer to this question: "What is the ASCO Effect"?

You see, there's an annual event that offers up some huge trading opportunities, courtesy of the American Society of Clinical Oncology (ASCO).

ASCO's annual meeting always seems to have everyone's ears. That's because its "ASCO Effect" has been known to benefit biotech stocks that reveal news at the conference.

In fact, some stocks surge more than 200% in the weeks leading up to the event.

This year's meeting will be held in Chicago from June 1-June 5 - and some stocks already have started to run.

If you're interested in cashing in on this biotech stock profit opportunity, here's what you need to know.

Importance of ASCO

Created in 1964, ASCO is a not-for-profit organization started by a group of physicians from the American Association of Cancer Research (AACR). They saw a need for a professional oncology society and set out with a mission to "conquer cancer through research, education, prevention and delivery of high quality patient care."

Today, the Arlington, VA-based global organization has almost 30,000 members with 25% coming from over 100 countries. The diverse group includes clinical oncologists from all oncology specialties, sub-specialists and oncology healthcare professionals such as nurses and health care practitioners.

At ASCO's annual four-day meeting, usually held in early June, tens of thousands of attendees share ideas and learn about cancer breakthroughs from therapies and diagnostics. It also includes presentations from more than 4,000 scientific abstracts.

The organization has attracted top clinicians and investigators to administer patient care and conduct research. On its website, the organization boasts that it "will be recognized as the most trusted source of cancer information worldwide."

But it's much more than a source for thorough cancer research. Those in the biotechnology industry keep a keen eye on the ASCO meeting.

That's because of the more than 600 medicines and vaccines developed through biotechnology and clinical trials, a large majority (254) deal with cancer treatments, according to the Pharmaceutical Research and Manufacturers of America.

Behind heart disease, cancer is the No.2 cause of U.S. deaths.

The need for cancer treatments is high with an estimated 1.6 million new cancer cases to be diagnosed in 2012 while more than 577,000 Americans will die from it.

From an economic standpoint, cancer is expensive. The National Institutes of Health (NIH) estimates that the overall cancer costs of 2007 were $226.8 billion.

So for biotechnology companies focused on cancer drugs, this time of year is one that could bring a doubling or tripling of their stock price until the conclusion of the ASCO meeting.

That gain is what has been known as the ASCO Effect.

To continue reading, please click here...